What is Xhance, and what does it treat?
Xhance is a prescription nasal spray that contains fluticasone (a corticosteroid) for treating nasal inflammation related to chronic rhinosinusitis with nasal polyps (CRSwNP). It is used to reduce symptoms such as nasal congestion and blockage caused by inflammation and swelling in the sinuses and nasal passages [1].
How is Xhance different from other fluticasone nasal sprays (like Flonase)?
Xhance uses a device designed to deliver fluticasone to the upper nasal cavity and sinuses differently than some standard nasal sprays. The medication’s active ingredient is still fluticasone, but the product’s delivery approach is meant to improve how the medicine reaches targeted areas in the nose/sinus region compared with typical bottle-and-spray products [1].
Who can use Xhance, and what are the common patient questions?
Patients typically ask whether it’s safe for long-term use and how quickly symptoms improve. As a corticosteroid, Xhance is generally intended for ongoing symptom control rather than short-term relief, and symptom improvement often takes days to reach more noticeable effect, though the exact timing can vary by person and condition [1].
Because it’s a steroid, patients also commonly ask about potential local side effects in the nose (such as irritation) and systemic concerns; clinicians weigh risks for each patient based on overall health and other medications [1].
What are key safety considerations with Xhance?
As a corticosteroid nasal therapy, Xhance can cause side effects related to nasal administration (for example, irritation or bleeding) and may affect the risk profile for certain patients. Safety guidance includes using it as prescribed and informing clinicians about other steroid use or medical conditions [1].
Is Xhance still on patent, and who makes it?
If you’re researching intellectual property or market status, DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and can help you find the relevant patent timelines for Xhance [2].
Sources:
[1] https://www.xhance.com/
[2] https://www.drugpatentwatch.com/